ANAPTYSBIO, INC. Research and Development Expense
ANAPTYSBIO, INC. (ANAB) reported Research and Development Expense of $31.41 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-04
- ANAPTYSBIO, INC. research and development expense for the quarter ending 2025-09-30 was $31.41M, a 25.60% decline year-over-year.
- ANAPTYSBIO, INC. research and development expense for the quarter ending 2025-06-30 was $37.82M, a 9.94% decline year-over-year.
- ANAPTYSBIO, INC. research and development expense for the quarter ending 2025-03-31 was $41.18M, a 11.17% increase year-over-year.
- ANAPTYSBIO, INC. research and development expense for the quarter ending 2024-09-30 was $42.21M, a 36.71% increase year-over-year.
- ANAPTYSBIO, INC. research and development expense for fiscal 2022 was $88.80M, a 9.85% decline from fiscal 2021.
- ANAPTYSBIO, INC. research and development expense for fiscal 2021 was $98.50M, a 23.08% increase from fiscal 2020.
- ANAPTYSBIO, INC. research and development expense for fiscal 2020 was $80.03M, a 19.44% decline from fiscal 2019.
- ANAPTYSBIO, INC. research and development expense for fiscal 2019 was $99.34M, a 76.77% increase from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $31.41M 10-Q · filed 2025-11-04 | $69.23M derived: sum of 2 quarters · filed 2025-11-04 | $110.41M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $37.82M 10-Q · filed 2025-08-06 | $79.00M 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | $41.18M 10-Q · filed 2025-05-05 | |||
| 2024-09-30 | $42.21M 10-Q · filed 2025-11-04 | $84.21M derived: sum of 2 quarters · filed 2025-11-04 | $121.25M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $42.00M 10-Q · filed 2025-08-06 | $79.04M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $37.04M 10-Q · filed 2025-05-05 | |||
| 2023-09-30 | $30.88M 10-Q · filed 2024-11-05 | $63.80M derived: sum of 2 quarters · filed 2024-11-05 | $98.76M 10-Q · filed 2024-11-05 | $122.13M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $32.92M 10-Q · filed 2024-08-05 | $67.88M 10-Q · filed 2024-08-05 | $91.25M derived: sum of 3 quarters · filed 2024-08-05 | $113.32M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $34.96M 10-Q · filed 2024-05-09 | $58.33M derived: sum of 2 quarters · filed 2024-05-09 | $80.39M derived: sum of 3 quarters · filed 2024-05-09 | $101.24M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $45.44M derived: sum of 2 quarters · filed 2023-11-02 | $66.28M derived: sum of 3 quarters · filed 2023-11-02 | $88.80M 10-K · filed 2023-03-01 |
| 2022-09-30 | $22.06M 10-Q · filed 2023-11-02 | $42.91M derived: sum of 2 quarters · filed 2023-11-02 | $65.42M 10-Q · filed 2023-11-02 | $92.20M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $20.84M 10-Q · filed 2023-08-07 | $43.36M 10-Q · filed 2023-08-07 | $70.14M derived: sum of 3 quarters · filed 2023-08-07 | $92.36M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $22.52M 10-Q · filed 2023-05-11 | $49.29M derived: sum of 2 quarters · filed 2023-05-11 | $71.51M derived: sum of 3 quarters · filed 2023-05-11 | $96.83M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $26.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $49.00M derived: sum of 2 quarters · filed 2023-03-01 | $74.31M derived: sum of 3 quarters · filed 2023-03-01 | $98.50M 10-K · filed 2023-03-01 |
| 2021-09-30 | $22.22M 10-Q · filed 2022-11-08 | $47.53M derived: sum of 2 quarters · filed 2022-11-08 | $71.72M 10-Q · filed 2022-11-08 | $93.29M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $25.31M 10-Q · filed 2022-08-08 | $49.50M 10-Q · filed 2022-08-08 | $71.07M derived: sum of 3 quarters · filed 2023-03-01 | $90.61M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $24.18M 10-Q · filed 2022-05-04 | $45.75M derived: sum of 2 quarters · filed 2023-03-01 | $65.29M derived: sum of 3 quarters · filed 2023-03-01 | $83.24M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $21.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $41.11M derived: sum of 2 quarters · filed 2023-03-01 | $59.06M derived: sum of 3 quarters · filed 2023-03-01 | $80.03M 10-K · filed 2023-03-01 |
| 2020-09-30 | $19.54M 10-Q · filed 2021-11-04 | $37.49M derived: sum of 2 quarters · filed 2021-11-04 | $58.46M 10-Q · filed 2021-11-04 | $79.88M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | $17.95M 10-Q · filed 2021-08-09 | $38.92M 10-Q · filed 2021-08-09 | $60.34M derived: sum of 3 quarters · filed 2022-03-07 | $90.27M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | $20.97M 10-Q · filed 2021-05-04 | $42.39M derived: sum of 2 quarters · filed 2022-03-07 | $72.33M derived: sum of 3 quarters · filed 2022-03-07 | $99.67M derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | $21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $51.36M derived: sum of 2 quarters · filed 2022-03-07 | $78.71M derived: sum of 3 quarters · filed 2022-03-07 | $99.34M 10-K · filed 2022-03-07 |
| 2019-09-30 | $29.93M 10-Q · filed 2020-11-04 | $57.28M derived: sum of 2 quarters · filed 2020-11-04 | $77.91M 10-Q · filed 2020-11-04 | $93.83M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $27.35M 10-Q · filed 2020-08-10 | $47.98M 10-Q · filed 2020-08-10 | $63.90M derived: sum of 3 quarters · filed 2021-02-25 | $81.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $20.63M 10-Q · filed 2020-05-06 | $36.55M derived: sum of 2 quarters · filed 2021-02-25 | $54.43M derived: sum of 3 quarters · filed 2021-02-25 | $65.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $15.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $33.80M derived: sum of 2 quarters · filed 2021-02-25 | $44.39M derived: sum of 3 quarters · filed 2021-02-25 | $56.20M 10-K · filed 2021-02-25 |
| 2018-09-30 | $17.88M 10-Q · filed 2019-11-08 | $28.47M derived: sum of 2 quarters · filed 2019-11-08 | $40.28M 10-Q · filed 2019-11-08 | $47.88M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $10.58M 10-Q · filed 2019-08-08 | $22.39M 10-Q · filed 2019-08-08 | $30.00M derived: sum of 3 quarters · filed 2020-03-02 | $36.70M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $11.81M 10-Q · filed 2019-05-07 | $19.42M derived: sum of 2 quarters · filed 2020-03-02 | $26.11M derived: sum of 3 quarters · filed 2020-03-02 | $33.32M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $14.30M derived: sum of 2 quarters · filed 2020-03-02 | $21.51M derived: sum of 3 quarters · filed 2020-03-02 | $29.44M 10-K · filed 2020-03-02 |
| 2017-09-30 | $6.70M 10-Q · filed 2018-11-08 | $13.90M derived: sum of 2 quarters · filed 2018-11-08 | $21.84M 10-Q · filed 2018-11-08 | $26.85M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $7.21M 10-Q · filed 2018-08-07 | $15.14M 10-Q · filed 2018-08-07 | $20.16M derived: sum of 3 quarters · filed 2019-02-28 | $23.44M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $7.93M 10-Q · filed 2018-05-08 | $12.95M derived: sum of 2 quarters · filed 2019-02-28 | $16.23M derived: sum of 3 quarters · filed 2019-02-28 | $18.57M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $8.30M derived: sum of 2 quarters · filed 2019-02-28 | $10.63M derived: sum of 3 quarters · filed 2019-02-28 | $15.42M 10-K · filed 2019-02-28 |
| 2016-09-30 | $3.28M 10-Q · filed 2017-11-07 | $5.62M derived: sum of 2 quarters · filed 2017-11-07 | $10.40M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $2.33M 10-Q · filed 2017-08-10 | $7.12M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $4.79M 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $17.30M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |